Ignet

Gene Information

Gene symbol: PPBP

Gene name: pro-platelet basic protein (chemokine (C-X-C motif) ligand 7)

HGNC ID: 9240

Synonyms: SCYB7, TGB, NAP-2-L1, LA-PF4, MDGF, LDGF, Beta-TG, CTAP3, CXCL7, PBP, b-TG1, TGB1, CTAPIII, NAP-2

Related Genes

#	Gene Symbol	Number of hits
1	C8orf4	1 hits
2	CCL11	1 hits
3	CCL17	1 hits
4	CCL18	1 hits
5	CCL2	1 hits
6	CCL22	1 hits
7	CCL23	1 hits
8	CCL24	1 hits
9	CCL27	1 hits
10	CCL3	1 hits
11	CCL4	1 hits
12	CD27	1 hits
13	CD4	1 hits
14	CD8A	1 hits
15	CSF2	1 hits
16	CXCL10	1 hits
17	CXCL11	1 hits
18	CXCL16	1 hits
19	CXCL3	1 hits
20	CXCL5	1 hits
21	FAS	1 hits
22	FASLG	1 hits
23	HLX	1 hits
24	IFNG	1 hits
25	IL10	1 hits
26	IL2RA	1 hits
27	IL6	1 hits
28	IL8	1 hits
29	MLC1	1 hits
30	PDCD1	1 hits
31	PF4	1 hits
32	PF4V1	1 hits
33	SPP1	1 hits
34	TBX21	1 hits
35	TGFB1	1 hits
36	TH1L	1 hits

Related Sentences

#	PMID	Sentence
1	14619487	However, the existence of an immunosuppressive state in cancer individuals leads to anergy and immunotolerance, which has been reported to be caused by T cell and DC immunosuppressive subsets or cytokines such as Th2, Tc2, CD4+CD25+, DC2 and IL-10 against Th1, Tc1, DC1 and IL-12.
2	15553669	Monocytes were separated from the peripheral blood collected by leukapheresis, and were cultured with GM-CSF and IL-4 for 6 days.
3	15553669	Then, TNF-alpha, IL-1beta, IL-6 and PGE2 were added for maturation of DC.
4	15553669	Th1/Th2 and Tc1/Tc2 balances improved in six of the nine patients after vaccination.
5	15553669	In this study, it was shown that immunosuppressive factors, such as IAP and TGF-beta, and Th1 balance are useful as markers of immunomonitoring for tumor-DC fusion vaccine in patients with advanced or recurrent gastrointestinal patients.
6	16207532	Experimental approaches to mediate GVT effects while limiting GVHD include: (1) allograft T cell depletion followed by immune enhancement; (2) modulation of T cell dose or T cell subset composition; (3) donor lymphocyte infusion; (4) reduced-intensity host preparation; (5) modulation of Th1/Th2 and Tc1/Tc2 cell balance; (6) cytokine therapy or neutralization; (7) T regulatory cell therapy; (8) co-stimulatory pathway modulation; (9) chemokine pathway modulation; (10) induction of antigen-specific T cells; (11) alloreactive NK cell therapy; and (12) targeted pharmaceutical inhibition of proteosome, mammalian target of rapamycin, and histone deacetylase pathways.
7	16412049	Novel roles of osteopontin and CXC chemokine ligand 7 in the defence against mycobacterial infection.
8	16412049	Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced human monocyte-derived macrophage (GM-Mphi) or macrophage CSF (M-CSF)-induced human monocyte-derived Mphi (M-Mphi) are distinct in terms of the resistance to Mycobacterium tuberculosis.
9	16412049	FN1 and FCGR2B were the most up-regulated genes in GM-Mphi and M-Mphi, respectively.
10	16412049	After stimulation with BCG, three chemokine genes (Osteopontin (SPP1), CXC chemokine ligand 7 (CXCL7) and CC chemokine ligand 11 (CCL11)) were highly expressed in M-Mphi-BCG when compared to those in GM-Mphi-BCG.
11	16412049	A significantly increased resistance to M. tuberculosis H37Ra was observed after the stimulation of GM-Mphi with SPP1 or CXCL7.
12	16412049	Superoxide production levels of SPP1- or CXCL7-stimulated GM-Mphis were higher than those of GM-Mphis without stimulation.
13	16412049	These results indicate that both SPP1 and CXCL7 might have a role in the resistance against mycobacteria, at least in part, through augmenting reactive oxygen intermediate production in Mphis.
14	16412049	Novel roles of osteopontin and CXC chemokine ligand 7 in the defence against mycobacterial infection.
15	16412049	Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced human monocyte-derived macrophage (GM-Mphi) or macrophage CSF (M-CSF)-induced human monocyte-derived Mphi (M-Mphi) are distinct in terms of the resistance to Mycobacterium tuberculosis.
16	16412049	FN1 and FCGR2B were the most up-regulated genes in GM-Mphi and M-Mphi, respectively.
17	16412049	After stimulation with BCG, three chemokine genes (Osteopontin (SPP1), CXC chemokine ligand 7 (CXCL7) and CC chemokine ligand 11 (CCL11)) were highly expressed in M-Mphi-BCG when compared to those in GM-Mphi-BCG.
18	16412049	A significantly increased resistance to M. tuberculosis H37Ra was observed after the stimulation of GM-Mphi with SPP1 or CXCL7.
19	16412049	Superoxide production levels of SPP1- or CXCL7-stimulated GM-Mphis were higher than those of GM-Mphis without stimulation.
20	16412049	These results indicate that both SPP1 and CXCL7 might have a role in the resistance against mycobacteria, at least in part, through augmenting reactive oxygen intermediate production in Mphis.
21	16412049	Novel roles of osteopontin and CXC chemokine ligand 7 in the defence against mycobacterial infection.
22	16412049	Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced human monocyte-derived macrophage (GM-Mphi) or macrophage CSF (M-CSF)-induced human monocyte-derived Mphi (M-Mphi) are distinct in terms of the resistance to Mycobacterium tuberculosis.
23	16412049	FN1 and FCGR2B were the most up-regulated genes in GM-Mphi and M-Mphi, respectively.
24	16412049	After stimulation with BCG, three chemokine genes (Osteopontin (SPP1), CXC chemokine ligand 7 (CXCL7) and CC chemokine ligand 11 (CCL11)) were highly expressed in M-Mphi-BCG when compared to those in GM-Mphi-BCG.
25	16412049	A significantly increased resistance to M. tuberculosis H37Ra was observed after the stimulation of GM-Mphi with SPP1 or CXCL7.
26	16412049	Superoxide production levels of SPP1- or CXCL7-stimulated GM-Mphis were higher than those of GM-Mphis without stimulation.
27	16412049	These results indicate that both SPP1 and CXCL7 might have a role in the resistance against mycobacteria, at least in part, through augmenting reactive oxygen intermediate production in Mphis.
28	16412049	Novel roles of osteopontin and CXC chemokine ligand 7 in the defence against mycobacterial infection.
29	16412049	Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced human monocyte-derived macrophage (GM-Mphi) or macrophage CSF (M-CSF)-induced human monocyte-derived Mphi (M-Mphi) are distinct in terms of the resistance to Mycobacterium tuberculosis.
30	16412049	FN1 and FCGR2B were the most up-regulated genes in GM-Mphi and M-Mphi, respectively.
31	16412049	After stimulation with BCG, three chemokine genes (Osteopontin (SPP1), CXC chemokine ligand 7 (CXCL7) and CC chemokine ligand 11 (CCL11)) were highly expressed in M-Mphi-BCG when compared to those in GM-Mphi-BCG.
32	16412049	A significantly increased resistance to M. tuberculosis H37Ra was observed after the stimulation of GM-Mphi with SPP1 or CXCL7.
33	16412049	Superoxide production levels of SPP1- or CXCL7-stimulated GM-Mphis were higher than those of GM-Mphis without stimulation.
34	16412049	These results indicate that both SPP1 and CXCL7 might have a role in the resistance against mycobacteria, at least in part, through augmenting reactive oxygen intermediate production in Mphis.
35	16412049	Novel roles of osteopontin and CXC chemokine ligand 7 in the defence against mycobacterial infection.
36	16412049	Granulocyte-macrophage colony-stimulating factor (GM-CSF)-induced human monocyte-derived macrophage (GM-Mphi) or macrophage CSF (M-CSF)-induced human monocyte-derived Mphi (M-Mphi) are distinct in terms of the resistance to Mycobacterium tuberculosis.
37	16412049	FN1 and FCGR2B were the most up-regulated genes in GM-Mphi and M-Mphi, respectively.
38	16412049	After stimulation with BCG, three chemokine genes (Osteopontin (SPP1), CXC chemokine ligand 7 (CXCL7) and CC chemokine ligand 11 (CCL11)) were highly expressed in M-Mphi-BCG when compared to those in GM-Mphi-BCG.
39	16412049	A significantly increased resistance to M. tuberculosis H37Ra was observed after the stimulation of GM-Mphi with SPP1 or CXCL7.
40	16412049	Superoxide production levels of SPP1- or CXCL7-stimulated GM-Mphis were higher than those of GM-Mphis without stimulation.
41	16412049	These results indicate that both SPP1 and CXCL7 might have a role in the resistance against mycobacteria, at least in part, through augmenting reactive oxygen intermediate production in Mphis.
42	17291641	Effect of allergen-specific immunotherapy on plasma level of platelet factor 4 (PF-4) and beta-thromboglobulin (beta-TG), platelet activation markers in patients with house dust mite allergy.
43	17291641	Plasma levels of PF-4 and beta-TG, platelet activation markers were measured using commercial ELISA kit.
44	17291641	PF-4 and beta-TG basal levels were not significantly different between the patients and the healthy subjects.
45	17291641	Thus, it seems that the degree of platelet activation measured by PF-4 and beta-TG does not change in PAR patients during hyposensitization with mite allergen extracts, after the maximum dose was reached.
46	17291641	Effect of allergen-specific immunotherapy on plasma level of platelet factor 4 (PF-4) and beta-thromboglobulin (beta-TG), platelet activation markers in patients with house dust mite allergy.
47	17291641	Plasma levels of PF-4 and beta-TG, platelet activation markers were measured using commercial ELISA kit.
48	17291641	PF-4 and beta-TG basal levels were not significantly different between the patients and the healthy subjects.
49	17291641	Thus, it seems that the degree of platelet activation measured by PF-4 and beta-TG does not change in PAR patients during hyposensitization with mite allergen extracts, after the maximum dose was reached.
50	17291641	Effect of allergen-specific immunotherapy on plasma level of platelet factor 4 (PF-4) and beta-thromboglobulin (beta-TG), platelet activation markers in patients with house dust mite allergy.
51	17291641	Plasma levels of PF-4 and beta-TG, platelet activation markers were measured using commercial ELISA kit.
52	17291641	PF-4 and beta-TG basal levels were not significantly different between the patients and the healthy subjects.
53	17291641	Thus, it seems that the degree of platelet activation measured by PF-4 and beta-TG does not change in PAR patients during hyposensitization with mite allergen extracts, after the maximum dose was reached.
54	17291641	Effect of allergen-specific immunotherapy on plasma level of platelet factor 4 (PF-4) and beta-thromboglobulin (beta-TG), platelet activation markers in patients with house dust mite allergy.
55	17291641	Plasma levels of PF-4 and beta-TG, platelet activation markers were measured using commercial ELISA kit.
56	17291641	PF-4 and beta-TG basal levels were not significantly different between the patients and the healthy subjects.
57	17291641	Thus, it seems that the degree of platelet activation measured by PF-4 and beta-TG does not change in PAR patients during hyposensitization with mite allergen extracts, after the maximum dose was reached.
58	17505023	Induction of a distinct CD8 Tnc17 subset by transforming growth factor-beta and interleukin-6.
59	17505023	Cross-talk between TGF-beta and IL-6 has been shown to direct the differentiation of CD4(+) cells into special IL-17-secreting cells, which are termed Th17 cells.
60	17505023	In this study, we demonstrated that TGF-beta and IL-6 could stimulate CD8(+) cells to differentiate into noncytotoxic, IL-17-producing cells in MLC.
61	17505023	These IL-17-producing CD8(+) cells exhibit a unique granzyme B(-)IFN-gamma(-)IL-10(-) phenotype.
62	17505023	The mRNA level of Th2/T cytotoxic 2 (Tc2) transcription factors GATA3 and Th1/Tc1 transcription factors T-box expressed in T cell (T-bet) as well as its target H2.O-like homeobox (Hlx) is decreased in CD8(+) cells from TGF-beta- and IL-6-treated MLC.
63	17505023	In addition, these CD8(+) cells display a marked up-regulation of retinoic acid-related orphan receptor-gammat, a key IL-17 transcription factor.
64	17505023	These results demonstrate that the existence of an IL-17-producing CD8(+) subset belongs to neither the Tc1 nor the Tc2 subset and can be categorized as a T noncytotoxic 17 (Tnc17) subset.
65	18094967	BALB/c mice received three preventive intraperitoneal immunizations with Mage-b DNA vaccine mixed with plasmid DNA, secreting granulocyte-macrophage colony stimulating factor (GM-CSF).
66	18094967	Immunization with Mage-b/GM-CSF/TGB significantly reduced the number of metastases by 67% compared to the saline/GM-CSF/TGB and by 69% compared to the vector control/GM-CSF/TGB.
67	18094967	Also, tumor growth was significantly reduced by 45% in mice vaccinated with Mage-b/GM-CSF/TGB compared to the saline/ GM-CSF/TGB and by 47% compared to the control vector/ GM-CSF/TGB group.
68	18094967	In vivo, the number of CD8 T cells significantly increased in the primary tumors and metastases of mice vaccinated with Mage-b/GM-CSF/TGB compared to the saline/GM-CSF/TGB and the control vector/ GM-CSF/TGB group, while the number of CD4 T cells significantly decreased.
69	18094967	The combination of Mage-b, GM-CSF and TGB did not only induce significantly higher levels of IFNgamma in the lymph nodes of vaccinated compared to control mice, but also induced significantly higher expression levels of Fas-ligand (FasL) in the primary tumors (expressing Fas protein constitutively), compared to the control mice.
70	18094967	Whether the interaction between Fas and FasL may have contributed to the smaller tumors needs to be further analyzed.
71	18094967	BALB/c mice received three preventive intraperitoneal immunizations with Mage-b DNA vaccine mixed with plasmid DNA, secreting granulocyte-macrophage colony stimulating factor (GM-CSF).
72	18094967	Immunization with Mage-b/GM-CSF/TGB significantly reduced the number of metastases by 67% compared to the saline/GM-CSF/TGB and by 69% compared to the vector control/GM-CSF/TGB.
73	18094967	Also, tumor growth was significantly reduced by 45% in mice vaccinated with Mage-b/GM-CSF/TGB compared to the saline/ GM-CSF/TGB and by 47% compared to the control vector/ GM-CSF/TGB group.
74	18094967	In vivo, the number of CD8 T cells significantly increased in the primary tumors and metastases of mice vaccinated with Mage-b/GM-CSF/TGB compared to the saline/GM-CSF/TGB and the control vector/ GM-CSF/TGB group, while the number of CD4 T cells significantly decreased.
75	18094967	The combination of Mage-b, GM-CSF and TGB did not only induce significantly higher levels of IFNgamma in the lymph nodes of vaccinated compared to control mice, but also induced significantly higher expression levels of Fas-ligand (FasL) in the primary tumors (expressing Fas protein constitutively), compared to the control mice.
76	18094967	Whether the interaction between Fas and FasL may have contributed to the smaller tumors needs to be further analyzed.
77	18094967	BALB/c mice received three preventive intraperitoneal immunizations with Mage-b DNA vaccine mixed with plasmid DNA, secreting granulocyte-macrophage colony stimulating factor (GM-CSF).
78	18094967	Immunization with Mage-b/GM-CSF/TGB significantly reduced the number of metastases by 67% compared to the saline/GM-CSF/TGB and by 69% compared to the vector control/GM-CSF/TGB.
79	18094967	Also, tumor growth was significantly reduced by 45% in mice vaccinated with Mage-b/GM-CSF/TGB compared to the saline/ GM-CSF/TGB and by 47% compared to the control vector/ GM-CSF/TGB group.
80	18094967	In vivo, the number of CD8 T cells significantly increased in the primary tumors and metastases of mice vaccinated with Mage-b/GM-CSF/TGB compared to the saline/GM-CSF/TGB and the control vector/ GM-CSF/TGB group, while the number of CD4 T cells significantly decreased.
81	18094967	The combination of Mage-b, GM-CSF and TGB did not only induce significantly higher levels of IFNgamma in the lymph nodes of vaccinated compared to control mice, but also induced significantly higher expression levels of Fas-ligand (FasL) in the primary tumors (expressing Fas protein constitutively), compared to the control mice.
82	18094967	Whether the interaction between Fas and FasL may have contributed to the smaller tumors needs to be further analyzed.
83	18094967	BALB/c mice received three preventive intraperitoneal immunizations with Mage-b DNA vaccine mixed with plasmid DNA, secreting granulocyte-macrophage colony stimulating factor (GM-CSF).
84	18094967	Immunization with Mage-b/GM-CSF/TGB significantly reduced the number of metastases by 67% compared to the saline/GM-CSF/TGB and by 69% compared to the vector control/GM-CSF/TGB.
85	18094967	Also, tumor growth was significantly reduced by 45% in mice vaccinated with Mage-b/GM-CSF/TGB compared to the saline/ GM-CSF/TGB and by 47% compared to the control vector/ GM-CSF/TGB group.
86	18094967	In vivo, the number of CD8 T cells significantly increased in the primary tumors and metastases of mice vaccinated with Mage-b/GM-CSF/TGB compared to the saline/GM-CSF/TGB and the control vector/ GM-CSF/TGB group, while the number of CD4 T cells significantly decreased.
87	18094967	The combination of Mage-b, GM-CSF and TGB did not only induce significantly higher levels of IFNgamma in the lymph nodes of vaccinated compared to control mice, but also induced significantly higher expression levels of Fas-ligand (FasL) in the primary tumors (expressing Fas protein constitutively), compared to the control mice.
88	18094967	Whether the interaction between Fas and FasL may have contributed to the smaller tumors needs to be further analyzed.
89	18940198	While it is well established that CD4(+) T lymphocytes play a crucial role in the initiation, progression and persistence of asthma, the role of CD8(+) T cells is less understood.
90	18940198	CD8(+) T cells form functionally similar subsets which exhibit similar cytokine profiles as Th1 and Th2 cells, known as Tc1 and Tc2.
91	18940198	Evidence from animal studies suggest that CD8(+) T cells are capable of regulating IgE production through the induction of IL-12 and IL-18 production in dendritic cells, and that CD8(+) T cells may act to moderate Th2 polarisation within the localised lymph nodes during allergic sensitisation.
92	19450895	Targeted knock down of CCL22 and CCL17 by siRNA during DC differentiation and maturation affects the recruitment of T subsets.
93	19450895	Using the recently developed chemokine protein arrays, we analyzed 38 chemokines associated with monocyte-derived DC (MoDC), including the CC family (CCL2, CCL3, CCL4, CCL17, CCL18, CCL22, CCL23, CCL24, CCL27) and the CXC family (CXCL3, CXCL5, CXCL7, CXCL8, CXCL16) chemokines.
94	19450895	Our results indicate that MoDC largely inherit the chemokines constitutively expressed by monocytes, with a significant induction of CCL17, CCL22 and CCL23.
95	19450895	Spent culture supernatant collected from MoDC exhibited chemotatic abilities to activate CD4(+), CD8(+), and CD25(+) Foxp3(+) regulatory T cells (Tregs).
96	19450895	Selective knock down of CCL22 and CCL17 expression by siRNA decreased the ratios of CD4(+) to CD8(+), as well as the frequency of Tregs recruited by MoDC.
97	19552626	The specificity for human substrates is not restricted to IL-8, since we also detected in vitro protease activity for another CXC chemokine GRO-alpha (growth-related oncogene alpha), but not for NAP-2 (neutrophil-activating protein 2), SDF (stromal-cell-derived factor)-1alpha, PF-4 (platelet factor 4), I-TAC (interferon-gamma-inducible T-cell alpha-chemoattractant), IP-10 (interferon-gamma-inducible protein 10) and MCP-1 (monocyte chemoattractant protein 1).
98	24728077	PD-1/B7-H1 is an important inhibitory axis in the tumor microenvironment.
99	24728077	We observed that using anti-PD-1 antibody and a multipeptide vaccine (consisting of immunogenic peptides derived from breast cancer antigens, neu, legumain, and β-catenin) as a combination therapy regimen for the treatment of breast cancer-bearing mice prolonged the vaccine-induced progression-free survival period.
100	24728077	This prolonged survival was associated with increase in number of Tc1 and Tc2 CD8 T cells with memory precursor phenotype, CD27+IL-7RhiT-betlo, and decrease in number of PD-1+ dendritic cells (DC) in regressing tumors and enhanced antigen reactivity of tumor-infiltrating CD8 T cells.
101	24728077	It was also observed that blockade of PD-1 on tumor DCs enhanced IL-7R expression on CD8 T cells.
102	24728077	Taken together, our results suggest that PD-1 blockade enhances breast cancer vaccine efficacy by altering both CD8 T cell and DC components of the tumor microenvironment.